Trial Profile
A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 31 Jan 2021 Results assessing prediction of response in NSCLC patients by using high circulating regulatory T cells and TGF beta presented at the 2020 World Conference on Lung Cancer
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 15 Jun 2018 Results (n=33) published in the Journal of Clinical Oncology.